Clinical Trial Update: A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT [Phase 2]

View source ↗

Summary

Phase 2 study evaluating mavacamten in participants with heart failure with preserved ejection fraction and elevated NT-proBNP (with or without elevated cTnT) h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• CAMZYOS (MAVACAMTEN)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2025-03-20